This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): mesalazine, mesalamine, 5-ASA
Description: ROWASA (Mesalamine) Enema is first-line therapy for management of symptoms associated with active, mild to moderate distal ulcerative colitis, proctosigmoiditis, or ulcerative proctitis. ROWASA acts directly on the site of inflammation (colon lining).
Deal Structure: Rowasa was originally developed by Alaven.
In August 2010, Meda signed an agreement to acquire Alaven. Meda will pay 350 MUSD on a cash and debt free basis. The acquisition was closed in October 2010.
Meda and Mylan
In February 2016, Mylan announced a recommended public offer to the shareholders of Meda Aktiebolag to tender all their shares in Meda to Mylan. The total offer consideration consists of a combination of cash and Mylan ordinary shares with a value at announcement of SEK 165 per Meda share. The total value of the offer for all Meda shares, including Meda net debt, is approximately SEK 83.6 billion or USD 9.9 billion, which represents a multiple of approximately 8.9x 2015 adjusted EBITDA with synergies. The Offer is subject to the satisfaction of a number of customary conditions, including clearance from relevant competition authorities, and is expected to be completed by the end of the third quarter of 2016.
In August 2016, Mylan announced that...See full deal structure in Biomedtracker
Additional information available to subscribers only: